Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

A Watchful Eye on Biosecurity

Published: Monday, October 07, 2013
Last Updated: Monday, October 07, 2013
Bookmark and Share
Intended for government laboratory and pharmaceutical screening applications, BioSentinel now recommends the Infinite F500 to all its customers.

BioSentinel Pharmaceuticals, based in Madison, Wisconsin, USA, was founded in 2007 to develop and commercialize rapid, high sensitivity assays for the detection of the botulinum neurotoxins (BoNT). These toxins block neurotransmitter release at the presynaptic terminal of nerves, and are commonly used in the medical and cosmetic sectors, as well as having bioweapon potential. The Company offers a range of both biochemical and cell-based assays, which are used by the US Department of Defense for detection of bioterrorism agents, and by large pharmaceutical manufacturers for potency testing of BoNT-based drug products and substances.

Dr Ward Tucker, Director of Research and Development at BioSentinel, explained the Company’s approach: “Our assay technology is designed to measure the proteolytic activity of BoNT down to the low picomolar or femtomolar range. Based on fluorescence detection, our assay uses a conjugated cyan fluorescent protein/yellow fluorescent protein (CFP/YFP) substrate which is cleaved by BoNT. In the absence of any toxin, excitation of the CFP results in fluorescence from the YFP due to FRET between the two domains. If BoNT is present in the sample, it cleaves the protein conjugate, leading to an increase in CFP fluorescence and a corresponding decrease in YFP fluorescence. By measuring the ratio between the CFP and YFP, we are able to accurately quantify BoNT activity. This mechanism of detection is highly sensitive, and the assay has been developed as both a biochemical assay, BoTest™, and a cell-based test, BoCell™.”

“We initially developed the assay kits with a high end, monochromator-based reader, but we wanted a more cost-effective solution that we could recommend to customers using the assay for routine screening applications. Although the BoTest has fairly straightforward detection needs, the BoCell kit, like any adherent cell-based assay, has more complex testing requirements to ensure robust and consistent data. One of our primary requirements was a reader that could measure at multiple user-defined sites within each well, allowing us to compensate for natural variations in cell density across the well, as well as avoiding the areas where cells may have been displaced by pipetting.”

“We tested microplate readers from several manufacturers, and the Infinite F500 from Tecan was clearly the best match for our needs. The standard filter sets are well-suited to our assay, and it offers us the flexibility to optimize the number and location of reads within the well. The Z­optimization feature is also a bonus, as this automated function ensures that the maximum signal intensity is achieved, further improving the sensitivity of our assay at low BoNT concentrations. We wanted a reader that we could recommend to customers who did not already have fluorescence detection capabilities, so it had to be cost-effective, but the quality of the data achieved using the Infinite F500 was also superior to the competitors’ instruments for our assay kits. This, combined with Tecan’s excellent reputation and the fact that several other molecular diagnostic companies recommend Tecan readers, made the Infinite F500 the logical choice.”

“We are also very happy with the support we received form Tecan during the evaluation process. The Company’s local representative took the time to understand our exact requirements, and provided us with a very good overview of the benefits of each Infinite series reader for our application. We were given the option to test multiple systems, which is very important, as we would not either purchase or recommend an instrument that we hadn’t had the opportunity to test in routine operation. Since purchasing our instrument it has been in daily use by multiple users, and has proven both straightforward and reliable to operate. Although we use our own bespoke software to perform the data analysis, the instrument’s control software is certainly user-friendly; it is easy to set up and run protocols. The reader has also been reliable over the last couple of years, we’ve not had any issues in terms of functionality and it always performs exactly as we expect.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Phenomenex,Tecan Partner
Phenomenex, Inc. and the Tecan Group has announced a collaboration to co-market automated solid phase extraction (SPE) sample preparation solutions.
Wednesday, September 09, 2015
Too Gracious a Host
Scientists at the University of Toronto are using Tecan’s Infinite M200 PRO and Gas Control Module to study host-pathogen interactions for Legionella bacteria.
Monday, October 07, 2013
Investigating Protein Targets and Cellular Pathways in Yeasts
Scientists at the Donnelly Centre for Cellular and Biomolecular Research have chosen generations of Tecan microplate readers to monitor the effects of environmental or drug perturbation on molecularly barcoded yeasts.
Monday, October 07, 2013
Reprogramming Nature
Researchers in the Synthetic Biology Center at the Massachusetts Institute of Technology are using a Freedom EVO® workstation to aid the development of genetic circuits.
Monday, October 07, 2013
The Tecan-Fudan University Demo Lab opens in Shanghai
Tecan and Fudan University in Shanghai have joined forces to open a demonstration laboratory in the University’s School of Pharmacy.
Monday, June 24, 2013
Tecan Shows Ongoing Commitment to Clinical and Research Markets in China
Key opinion leaders from major hospital clinical laboratories in China recently visited Tecan’s European research and development centers.
Monday, June 24, 2013
Joining the Digital Age
TES Pharma has recently purchased an HP D300 Digital Dispenser, and is now reaping the benefits of direct titration with improved assay reproducibility and more time to perform exploratory research.
Thursday, February 21, 2013
Boston Plays Host to the Fifth Tecan Symposium
This year’s symposium explored the topic of ‘Mass spectrometry - the expanding role in life sciences and diagnostics.’
Wednesday, December 12, 2012
Tecan and Reinnervate Team up for Automation of 3D Cell Culture
Alvetex Scaffold for the automation of 3D cell culture.
Tuesday, June 26, 2012
Tecan Collaborates with China to Embrace a Whole New Dimension in Blood Safety
Tecan is working with the Chinese Society of Blood Transfusion in a bid to steadily improve both the capabilities and the quality of blood screening services.
Tuesday, May 22, 2012
Tecan and Attana Extend Distribution Agreement
Tecan to distribute Attana's label-free biosensor instruments and QCM assay technology in Europe.
Friday, October 14, 2011
Tecan and Covaris co-market Freedom EVO® with Adaptive Focused Acoustics™
The joint offering will be available to customers for sample preparation, compound management and next generation sequencing applications.
Friday, November 19, 2010
Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
New solution combines multiplexing and automation technologies to create novel system for newborn screening laboratories.
Friday, October 15, 2010
Tecan Automated Solutions Accelerate Crop Improvement
University of Kiel scientists use Tecan Freedom EVO® for the development of TILLING® programs for rape seed and sugar beet.
Friday, July 16, 2010
Tecan Provides Automated Solutions for Molecular Pharmacology
Leibniz-Institut uses Tecan’s Freedom EVO® workstations for systematic high throughput screening of bioactive small molecule libraries.
Tuesday, July 06, 2010
Scientific News
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
How Cell Growth Triggers Cell Division
Researchers in Jan Skotheim's lab have discovered a previously unknown mechanism that controls how large cells grow, an insight that could one day provide insight into attacking diseases such as cancer.
Microbe Sleuth
Tanja Bosak examines how life and the Earth evolved in tandem during their early history together.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos